FVIIa antagonists

Details FVIIa antagonists FVIIa antagonists

2006-08-01

2006-08-01

Weber, Jon (Department: 1653)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S824000, C435S007100, C530S300000, C530S326000, C530S325000, C530S324000

Reexamination Certificate

active

07084109

ABSTRACT:
This invention provides novel compounds which prevent or block a FVIIa mediated or associated process or event such as the catalytic conversion of FX to FXa, FVII to FVIIa or FIX to FIXa. In particular aspects, the compounds of the invention bind Factor VIIa (FVIIa), its zymogen Factor VII (FVII) and/or block the association of FVII or FVIIa with a peptide compound of the present invention. The invention also provides pharmaceutical compositions comprising the novel compounds as well as their use in diagnostic, therapeutic, and prophylactic methods.

REFERENCES:
patent: 5116964 (1992-05-01), Capon et al.
patent: 5336603 (1994-08-01), Capon et al.
patent: 5714147 (1998-02-01), Capon et al.
patent: 5759954 (1998-06-01), Taguchi et al.
patent: 5834244 (1998-11-01), Dennis et al.
patent: 5863893 (1999-01-01), Dennis et al.
patent: 5880256 (1999-03-01), Dennis et al.
patent: WO 90/03390 (1990-04-01), None
patent: WO 91/11514 (1991-08-01), None
patent: WO 95/00541 (1995-01-01), None
patent: WO 96/40779 (1996-12-01), None
patent: WO 97/20939 (1997-06-01), None
patent: WO 00/24782 (2000-05-01), None
Adams et al., “The genome sequence ofDrosophila melanogaster”Science(abstract only) 287(5461):2185-2195 (2000).
Badimon et al., “Hirudin and Other Thrombin Inhibitors: Experimental Results and Potential Clinical Applications”Trends Cardiovasc. Med.1(6):261-267 (1991).
Banner et al., “The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor”Nature380:41-46 (1996).
Bone, R. C., “Modulators of Coagulation: A Critical Appraisal of Their Role In Sepsis”Arch Intern Med152:1381-1389 (1992).
Carson and Brozna, “The role of tissue factor in the production of thrombin”Blood. Coag. Fibrinol4:281-292 (1993).
Clackson and Wells, “In vitro selection from protein and peptide libraries”Trends Biotechnol.12:173-184 (1994).
Colman, R. W., “The Role of Plasma Proteases In Septic Shock”The New England J. of Med.320(18):1207-1209 (1989).
Creasey et al., “Tissue Factor Pathway Inhibitor Reduces Mortality fromEscherichia coliSeptic Shock”J. Clin. Invest.91:2850-2860 (1993).
Davie et al., “The Coagulation Cascade: Initiation, Maitenance, and Regulation”Biochemistry30(43):10363-10370 (1991).
Dennis et al., “Peptide exosite inhibitors of factor VIIa as anticoagulants”Nature404:465-470 (2000).
Dickinson et al., “Influence of Cofactor Binding and Active Site Occupancy on the Conformation of the Macromolecular Substrate Exosite of Factor VIIa”J. Mol. Biol.277:959-971 (1998).
Hagen et al., “Characterization of a cDNA coding for human factor VII”Proc. Natl. Acad. Sci. USA83:2412-2416 (1986).
Harlos et al., “Crystal structure of the extracellular region of human tissue factor”Nature370:662-666 (1994).
Haskel et al., “Prevention of Arterial Reocclusion After Thrombolysis With Recombinant Lipoprotein-Associated Coagulation Inhibitor”Circulation84(2):821-827 (1991).
Higashi et al., “Identification of Regions of Bovine Factor VII Essential for Binding Tissue Factor”Journal of Biological Chemistry269:18891-18898 (1994).
Holst et al., “Antithrombotic Properties of a Truncated Recombinant Tissue Factor Pathway Inhibitor in an Experimental Venous Thrombosis Model”Haemostasis23(Suppl. 1):112-117 (1993).
Husbyn et al., “Peptides corresponding to the second epidermal growth factor-like domain of human blood coagulation factor VII: synthesis, folding and biological activity”J. Peptide Res.50:475-482 (1997).
Kelly et al., “Ca2+Binding to the First Epidermal Growth Factor Module Coagulation Factor VIIa Is Important for Cofactor Interaction and Proteolytic Function”Journal of Biological Chemistry272:17467-17472 (1997).
Lee et al., “Potent Bifunctional Anticoagulants: Kunitz Domain-Tissue Factor Fusion Proteins”Biochemistry36(19):5607-5611 (1997).
Lowman et al., “Molecular Mimics of Insulin-Like Growth Factor 1 (IGF-1) for Inhibiting IGF-1: IGF-Binding protein Interactions.”Biochemistry37(25):8870-8878 (1998).
Lowman, H., “Bacteriophage display and discovery of peptide leads for drug development”Annual Review of Biophysics and Biomolecular Structure26:401-424 (1997).
Mori et al., “Analysis of promoter activity of 5'-upstream regions of zebrafish olfactory receptor genes”Biol. Pharm. Bull.(abstract only) 23(2):165-173 (2000).
Muller et al., “Structure of the Extracellular Domain of Human Tissue Factor: Location of the Factor VIIa Binding Site”Biochemistry33(36):10864-10870 (1994).
O'Brien et al., “Factor VIII-Bypassing Activity of Bovine Tissue Factor Using the Canine Hemophilic Model”J. Clin. Invest.82:206-211 (1988).
Paborsky et al., “Lipid Association, but Not the Transmembrane Domain, Is Required for Tissue Factor Activity”Journal of Biological Chemistry266:21911-21916 (1991).
Rapaport and Rao, “Initiation and Regulation of Tissue Factor-Dependent Blood Coagulation”Arterioscler. Thromb.12(10):1111-1121 (1992).
Roy et al., “Self-association of Tissue Factor as Revealed by Chemical Cross-linking”Journal of Biological Chemistry266(8):4665-4668 (1991).
Rudinger, J., “Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence”Peptide Hormones, J.A. Parsons, Baltimore:University Park Press pp. 1-7 (1976).
Sawyer, T.K., “Peptidomimetic Design and Chemical Approaches to Peptide Metabolism”Peptide-Based Drug Design: Controlling Transport and Metabolism, Taylor and Amidon, Washington, DC:American Chemical Society pps. 387-422 (1995).
Scott and Smith, “Searching for peptide ligands with an epitope library”Science249:386-390 (1990).
Smith, G. P., “Surface presentation of protein epitopes using bacteriophage expression systems”Curr. Opin. Biotechnol.2(5):668-673 (1991).
Wells and Lowman, “Rapid evolution of peptide and protein binding properties in vitro”Curr. Opin. Biotechnol.3:355-362 (1992).
Wildgoose et al., “Identification of a Calcium Binding Site in the Protease Domain of Human Blood Coagulation Factor VII: Evidence for Its Role in Factor VII-Tissue Factor Interaction”Biochemistry32:114-119 (1993).
Dennis et al., 1994,The Journal of Biological Chemistry, 269(2) Issue of Sep. 2:22129-22136 “Kunitz Domain Inhibitors of Tissue Factor-Factor VIIa.”.
Lowman,Methods in Molecular Biology, 87:249-264 “Phage Display of Peptide Libraries on Protein Scaffolds.”.
Sidhu et al., 2000,Methods in Enzymology, 328:333-363 “[21] Phage Display for Selection of Novel Binding Peptides.”.
Singson et al., 1998,Cell, 93:71-79 “TheC. elegans spe-9Gene Encodes a Sperm Transmembrane Protein that contains EGF-like Repeats and Is Required for Fertilization.”.

Affiliated with

Also associated with

Rating

FVIIa antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with FVIIa antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and FVIIa antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3687136